Results 91 to 100 of about 26,315,175 (213)

Targeting KRAS for cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia   +4 more
wiley   +1 more source

Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts

open access: yes, 1993
Udgivelsesdato: 1993-JanWe examined a panel of 25 small cell lung cancer (SCLC) cell lines and nude mouse xenografts for expression of the proto-oncogenes c-met and c-kit, and for expression of the corresponding ligands, hepatocyte growth factor (HGF ...
Nakamura, T   +2 more
core   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

open access: yesBritish Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka   +3 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff   +3 more
wiley   +1 more source

Induction of C-Met Proto-Oncogene by Epstein-Barr Virus Latent Membrane Protein-1 and the Correlation with Cervical Lymph Node Metastasis of Nasopharyngeal Carcinoma

open access: yes, 2009
Nasopharyngeal carcinoma (NPC) is distinctive in head and neck carcinomas for its close association with Epstein-Barr virus and Its highly metastatic nature. Up-regulation of cell motility Is essential for enhancement of metastatic potential.
沈宗憲, SHEEN, TZUNG-SHIAHN
core  

The c‐Src inhibitor eCF506 diminishes opioid tolerance and reduces β‐arrestin2 recruitment

open access: yesBritish Journal of Pharmacology, EarlyView.
Morphine activation of μ receptors causes tolerance through c‐Src activation and β‐arrestin2 recruitment. c‐Src inhibition or degradation reduces β‐arrestin2 recruitment, μ receptor endocytosis, while causing receptor upregulation, all likely contributing to reduced morphine tolerance.
Samuel Singleton   +6 more
wiley   +1 more source

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

open access: yesCancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda   +9 more
wiley   +1 more source

TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776‐Altered Subtype of HER2‐Mutant NSCLC

open access: yesCancer Science, EarlyView.
A two‐stage clinicogenomic analysis identified and independently validated a preferential association between TERT promoter mutations and the ERBB2 G776‐altered subtype of HER2‐mutant NSCLC, highlighting subtype‐specific genomic heterogeneity. ABSTRACT HER2‐mutant non‐small cell lung cancer (NSCLC) comprises molecularly heterogeneous tumors with ...
Akihiro Yoshimura   +3 more
wiley   +1 more source

Dynamic Changes of ctDNA‐Based MRD and Genomic Mutations Predict Prognosis in ESCC Treated With Definitive Radiotherapy

open access: yesCancer Science, EarlyView.
In patients with esophageal squamous cell carcinoma receiving definitive radiotherapy combined with systemic therapy, posttreatment TP53 mutation clearance and ctDNA‐MRD negativity predict favorable outcomes, whereas persistent ctDNA signals indicate elevated relapse risk, supporting nucleosome‐ and MRD‐informed surveillance and risk‐stratification ...
Shutang Liu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy